1887

Abstract

The mortality of clinical infections necessitates consideration of the utility of a vaccine. We have found that species can act as a protective vaccine against a lethal systemic infection, and describe experiments optimizing a subcutaneous regimen with killed yeast. Three injections of 2.5 mg given a week apart, 2 weeks prior to challenge, consistently, significantly, provided survival protection and reduction of infection in organs in survivors. The protection was independent of the strain of , and possibly even the species, and could be demonstrated in several inbred (including C′-deficient) and outbred mouse strains. The protective moiety(ies) appeared to reside in the cell wall and was resistant to 100 °C, but not to protease or formalin. Alum potentiated the protection. The protection was comparable or superior to that of several -specific preparations described in the literature. Other studies have indicated that heat-killed can protect against infection with at least three other fungal genera, raising the possibility of development of a panfungal vaccine, and such a vehicle has been studied in clinical trials, without dose-limiting toxicity.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.033290-0
2011-10-01
2019-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/10/1423.html?itemId=/content/journal/jmm/10.1099/jmm.0.033290-0&mimeType=html&fmt=ahah

References

  1. Bernard M. , Latgé J. P. . ( 2001; ). Aspergillus fumigatus cell wall: composition and biosynthesis. . Med Mycol 39: (Suppl. 1), 9–17.[PubMed] [CrossRef]
    [Google Scholar]
  2. Bernstein M. B. , Chakraborty M. , Wansley E. K. , Guo Z. , Franzusoff A. , Mostböck S. , Sabzevari H. , Schlom J. , Hodge J. W. . ( 2008; ). Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. . Vaccine 26:, 509–521. [CrossRef] [PubMed]
    [Google Scholar]
  3. Bozza S. , Clavaud C. , Giovannini G. , Fontaine T. , Beauvais A. , Sarfati J. , D’Angelo C. , Perruccio K. , Bonifazi P. et al. ( 2009; ). Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. . J Immunol 183:, 2407–2414. [CrossRef] [PubMed]
    [Google Scholar]
  4. Capilla J. , Clemons K , Miller T. K. , Selitrennikoff C. , Stevens D. . ( 2006; ). Aspergillus fumigatus antigens and fungal elements as vaccines against aspergillosis in mice. . In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September, 2006, abstract no. G-153. Washington, DC, American Society for Microbiology.
    [Google Scholar]
  5. Capilla J. , Clemons K. V. , Liu M. , Levine H. B. , Stevens D. A. . ( 2009; ). Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. . Vaccine 27:, 3662–3668. [CrossRef] [PubMed]
    [Google Scholar]
  6. Capilla Luque J. C. , Clemons K. V. , Stevens D. A. . ( 2003; ). Efficacy of micafungin alone or in combination against systemic murine aspergillosis. . Antimicrob Agents Chemother 47:, 1452–1455. [CrossRef] [PubMed]
    [Google Scholar]
  7. Cenci E. , Mencacci A. , Bacci A. , Bistoni F. , Kurup V. P. , Romani L. . ( 2000; ). T cell vaccination in mice with invasive pulmonary aspergillosis. . J Immunol 165:, 381–388.[PubMed] [CrossRef]
    [Google Scholar]
  8. Clemons K. V. , Stevens D. A. . ( 2004; ). Comparative efficacies of four amphotericin B formulations – Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. . Antimicrob Agents Chemother 48:, 1047–1050. [CrossRef] [PubMed]
    [Google Scholar]
  9. Clemons K. V. , Stevens D. A. . ( 2005; ). The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. . Med Mycol 43: (Suppl. 1), S101–S110. [CrossRef] [PubMed]
    [Google Scholar]
  10. Clemons K. V. , Stevens D. A. . ( 2009; ). Conventional or molecular measurement of Aspergillus load. . Med Mycol 47: (Suppl. 1), S132–S137. [CrossRef] [PubMed]
    [Google Scholar]
  11. Clemons K. V. , McCusker J. H. , Davis R. W. , Stevens D. A. . ( 1994; ). Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae . . J Infect Dis 169:, 859–867. [CrossRef] [PubMed]
    [Google Scholar]
  12. Clemons K. V. , Park P. , McCusker J. H. , McCullough M. J. , Davis R. W. , Stevens D. A. . ( 1997; ). Application of DNA typing methods and genetic analysis to epidemiology and taxonomy of Saccharomyces isolates. . J Clin Microbiol 35:, 1822–1828.[PubMed]
    [Google Scholar]
  13. Clemons K. V. , Grunig G. , Sobel R. A. , Mirels L. F. , Rennick D. M. , Stevens D. A. . ( 2000; ). Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. . Clin Exp Immunol 122:, 186–191. [CrossRef] [PubMed]
    [Google Scholar]
  14. Clemons K. V. , Miller T. K. , Selitrennikoff C. P. , Stevens D. A. . ( 2002; ). fos-1, a putative histidine kinase as a virulence factor for systemic aspergillosis. . Med Mycol 40:, 259–262.[PubMed]
    [Google Scholar]
  15. Denning D. W. , Stevens D. A. . ( 1991; ). Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. . Antimicrob Agents Chemother 35:, 1329–1333.[PubMed] [CrossRef]
    [Google Scholar]
  16. Fierer J. , Waters C. , Walls L. . ( 2006; ). Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. . J Infect Dis 193:, 1323–1331. [CrossRef] [PubMed]
    [Google Scholar]
  17. Finn A. . ( 2004; ). Bacterial polysaccharide-protein conjugate vaccines. . Br Med Bull 70:, 1–14. [CrossRef] [PubMed]
    [Google Scholar]
  18. Franzusoff A. , Duke R. C. , King T. H. , Lu Y. , Rodell T. C. . ( 2005; ). Yeasts encoding tumour antigens in cancer immunotherapy. . Expert Opin Biol Ther 5:, 565–575. [CrossRef] [PubMed]
    [Google Scholar]
  19. Goldblatt D. . ( 2000; ). Conjugate vaccines. . Clin Exp Immunol 119:, 1–3. [CrossRef] [PubMed]
    [Google Scholar]
  20. Hanson L. H. , Clemons K. V. , Denning D. W. , Stevens D. A. . ( 1995; ). Efficacy of oral saperconazole in systemic murine aspergillosis. . J Med Vet Mycol 33:, 311–317. [CrossRef] [PubMed]
    [Google Scholar]
  21. Hearn V. M. , Escott G. M. , Evans E. G. V. , Adams D. J. . ( 1998; ). Complex chitinolytic system of Aspergillus fumigatus . . Microbios 93:, 85–104.[PubMed]
    [Google Scholar]
  22. Hector R. F. , Yee E. , Collins M. S. . ( 1990; ). Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. . Infect Immun 58:, 1476–1478.[PubMed]
    [Google Scholar]
  23. Heintel T. , Breinig F. , Schmitt M. J. , Meyerhans A. . ( 2003; ). Extensive MHC class I-restricted CD8 T lymphocyte responses against various yeast genera in humans. . FEMS Immunol Med Microbiol 39:, 279–286. [CrossRef] [PubMed]
    [Google Scholar]
  24. HogenEsch H. . ( 2002; ). Mechanisms of stimulation of the immune response by aluminum adjuvants. . Vaccine 20: (Suppl. 3), S34–S39. [CrossRef] [PubMed]
    [Google Scholar]
  25. Hunter R. L. . ( 2002; ). Overview of vaccine adjuvants: present and future. . Vaccine 20: (Suppl. 3), S7–S12. [CrossRef] [PubMed]
    [Google Scholar]
  26. Ito J. I. , Lyons J. M. , Hong T. B. , Tamae D. , Liu Y. K. , Wilczynski S. P. , Kalkum M. . ( 2006; ). Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. . Infect Immun 74:, 5075–5084. [CrossRef] [PubMed]
    [Google Scholar]
  27. Klis F. M. , Mol P. , Hellingwerf K. , Brul S. . ( 2002; ). Dynamics of cell wall structure in Saccharomyces cerevisiae . . FEMS Microbiol Rev 26:, 239–256. [CrossRef] [PubMed]
    [Google Scholar]
  28. Kuranda M. J. , Robbins P. W. . ( 1991; ). Chitinase is required for cell separation during growth of Saccharomyces cerevisiae . . J Biol Chem 266:, 19758–19767.[PubMed]
    [Google Scholar]
  29. Kurup V. P. , Ramasamy M. , Greenberger P. A. , Fink J. N. . ( 1988; ). Isolation and characterization of a relevant Aspergillus fumigatus antigen with IgG- and IgE-binding activity. . Int Arch Allergy Appl Immunol 86:, 176–182. [CrossRef] [PubMed]
    [Google Scholar]
  30. Lachin J. M. . ( 1999; ). Worst-rank score analysis with informatively missing observations in clinical trials. . Control Clin Trials 20:, 408–422. [CrossRef] [PubMed]
    [Google Scholar]
  31. Lees A. , Nelson B. L. , Mond J. J. . ( 1996; ). Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. . Vaccine 14:, 190–198. [CrossRef] [PubMed]
    [Google Scholar]
  32. Levine H. B. , Pappagianis D. , Cobb J. M. . ( 1970; ). Development of vaccines for coccidioidomycosis. . Mycopathol Mycol Appl 41:, 177–185. [CrossRef] [PubMed]
    [Google Scholar]
  33. Lin S. J. , Schranz J. , Teutsch S. M. . ( 2001; ). Aspergillosis case-fatality rate: systematic review of the literature. . Clin Infect Dis 32:, 358–366. [CrossRef] [PubMed]
    [Google Scholar]
  34. Liu M. , Machova E. , Nescakova Z. , Clemons K. , Martinez M. , Chen V. , Bystricky S. , Stevens D. A. . ( 2009; ). Vaccination with mannan protects mice against invasive aspergillosis. . In 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September, 2009, abstract no. G1-892. Washington, DC: American Society for Microbiology.
    [Google Scholar]
  35. Liu M. , Clemons K. , Bystricky S. , Stevens D. . ( 2010a; ). Glycans and conjugates as vaccines against coccidioidomycosis. . In 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, September, 2010, abstract no. G1-1657. Washington, DC: American Society for Microbiology.
    [Google Scholar]
  36. Liu M. , Clemons K. , Machova E. , Medovarska I. , Stevens D. . ( 2010b; ). Effect of different molecular sizes of mannan as vaccines against invasive aspergillosis. . In 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, September, 2010, abstract no. G1-1658. Washington, DC: American Society for Microbiology.
    [Google Scholar]
  37. Liu M. , Clemons K. , Johansen M. , Martinez M. , Chen V. , Stevens D. . ( 2010c; ). Saccharomyces as a vaccine against systemic candidiasis. . In 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, September, 2010, abstract no. G1-1656. Washington, DC: American Society for Microbiology.
    [Google Scholar]
  38. Liu M. , Clemons K. V. , Bigos M. , Medovarska I. , Brummer E. , Stevens D. A. . ( 2011; ). Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. . Vaccine 29:, 1745–1753. [CrossRef] [PubMed]
    [Google Scholar]
  39. Lu Y. , Bellgrau D. , Dwyer-Nield L. D. , Malkinson A. M. , Duke R. C. , Rodell T. C. , Franzusoff A. . ( 2004; ). Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. . Cancer Res 64:, 5084–5088. [CrossRef] [PubMed]
    [Google Scholar]
  40. Lucas A. H. , Apicella M. A. , Taylor C. E. . ( 2005; ). Carbohydrate moieties as vaccine candidates. . Clin Infect Dis 41:, 705–712. [CrossRef] [PubMed]
    [Google Scholar]
  41. Majumder, T., Liu, M., Chen, V., Martinez, M., Alvarado, D., Clemons, K. V. & Stevens, D. A. (2011). Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2011, abstract no. G1-769. Washington, DC: American Society for Microbiology.
  42. Mortimer R. K. , Johnston J. R. . ( 1986; ). Genealogy of principal strains of the yeast genetic stock center. . Genetics 113:, 35–43.[PubMed]
    [Google Scholar]
  43. Munson S. , Parker J. , King T. , Lu Y. , Kelley V. , Guo Z. , Borges V. , Franzusoff A. . ( 2007; ). Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. . In Cancer Vaccines and Tumor Immunity, pp. 131–149. Edited by Orentas R. , Hodge J. W. , Johnson B. D. . . Hoboken, NJ:: John Wiley & Sons;. [CrossRef]
    [Google Scholar]
  44. Pishko E. J. , Kirkland T. N. , Cole G. T. . ( 1995; ). Isolation and characterization of two chitinase-encoding genes (cts1, cts2) from the fungus Coccidioides immitis . . Gene 167:, 173–177. [CrossRef] [PubMed]
    [Google Scholar]
  45. Richard J. L. , Thurston J. R. , Cutlip R. C. , Pier A. C. . ( 1982; ). Vaccination studies of aspergillosis in turkeys: subcutaneous inoculation with several vaccine preparations followed by aerosol challenge exposure. . Am J Vet Res 43:, 488–492.[PubMed]
    [Google Scholar]
  46. Salehen N. , Stover C. . ( 2008; ). The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen. . Vaccine 26:, 451–459. [CrossRef] [PubMed]
    [Google Scholar]
  47. Shih W. . ( 2002; ). Problems in dealing with missing data and informative censoring in clinical trials. . Curr Control Trials Cardiovasc Med 3:, 4. [CrossRef] [PubMed]
    [Google Scholar]
  48. Stevens D. A. , Clemons K. V. , Liu M. . ( 2011; ). Developing a vaccine against aspergillosis. . Med Mycol 49: (Suppl. 1), S170–S176. [CrossRef] [PubMed]
    [Google Scholar]
  49. Stubbs A. C. , Martin K. S. , Coeshott C. , Skaates S. V. , Kuritzkes D. R. , Bellgrau D. , Franzusoff A. , Duke R. C. , Wilson C. C. . ( 2001; ). Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. . Nat Med 7:, 625–629. [CrossRef] [PubMed]
    [Google Scholar]
  50. Torosantucci A. , Bromuro C. , Chiani P. , De Bernardis F. , Berti F. , Galli C. , Norelli F. , Bellucci C. , Polonelli L. et al. ( 2005; ). A novel glyco-conjugate vaccine against fungal pathogens. . J Exp Med 202:, 597–606. [CrossRef] [PubMed]
    [Google Scholar]
  51. Walsh T. J. , Anaissie E. J. , Denning D. W. , Herbrecht R. , Kontoyiannis D. P. , Marr K. A. , Morrison V. A. , Segal B. H. , Steinbach W. J. et al. ( 2008; ). Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. . Clin Infect Dis 46:, 327–360. [CrossRef] [PubMed]
    [Google Scholar]
  52. Weaver D. J. Jr , Reis E. S. , Pandey M. K. , Köhl G. , Harris N. , Gerard C. , Köhl J. . ( 2010; ). C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. . Eur J Immunol 40:, 710–721. [CrossRef] [PubMed]
    [Google Scholar]
  53. Wightman R. , Meacock P. A. . ( 2003; ). The THI5 gene family of Saccharomyces cerevisiae: distribution of homologues among the hemiascomycetes and functional redundancy in the aerobic biosynthesis of thiamin from pyridoxine. . Microbiology 149:, 1447–1460. [CrossRef] [PubMed]
    [Google Scholar]
  54. Wuthrich M. , Filutowicz H. I. , Warner T. , Deepe G. S. Jr , Klein B. S. . ( 2003; ). Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. . J Exp Med 197:, 1405–1416. [CrossRef] [PubMed]
    [Google Scholar]
  55. Xue J. , Chen X. , Selby D. , Hung C. Y. , Yu J. J. , Cole G. T. . ( 2009; ). A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. . Infect Immun 77:, 3196–3208. [CrossRef] [PubMed]
    [Google Scholar]
  56. Zheng M. , Ramsay A. J. , Robichaux M. B. , Norris K. A. , Kliment C. , Crowe C. , Rapaka R. R. , Steele C. , McAllister F. et al. ( 2005; ). CD4+ T cell-independent DNA vaccination against opportunistic infections. . J Clin Invest 115:, 3536–3544. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.033290-0
Loading
/content/journal/jmm/10.1099/jmm.0.033290-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error